Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
39.1M
-
Shares change
-
-227K
-
Total reported value, excl. options
-
$231M
-
Value change
-
-$9.77M
-
Put/Call ratio
-
0.12
-
Number of buys
-
54
-
Number of sells
-
-46
-
Price
-
$5.90
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q4 2022
129 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q4 2022.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.1M shares
of 70.9M outstanding shares and own 55.16% of the company stock.
Largest 10 shareholders include ArrowMark Colorado Holdings LLC (5.8M shares), WASATCH ADVISORS INC (5.78M shares), BlackRock Inc. (3.62M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.93M shares), RTW INVESTMENTS, LP (2.82M shares), STATE STREET CORP (2.45M shares), Soleus Capital Management, L.P. (2.44M shares), VANGUARD GROUP INC (2.06M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), and GEODE CAPITAL MANAGEMENT, LLC (797K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.